The interest in ganetespib is absolutely incredible. The statements that really caught my eye were:
Synta has established over 100 academic, preclinical collaborations investigating the science and potential applications of ganetespib. Over two dozen clinical trials sponsored by investigators, cooperative groups, or patient foundations are ongoing or planned for 2014.
These facts lend to the credence and future success of ganetespib. The drug will eventually find usefulness in a number of cancer therapies. Outstanding news!!!
Agree with you. Ganetespib is a winner. Great news and like you said, it appears it will be used in many other cancer treatments not just restricted to one cancer. Very exciting for SNTA and investors.
It looks like the market is waking up to SNTA with the recent announcement and the boost from a hot biotech sector. When many people, mutual funds and other investment firms are prompted to do some due diligence on a stock like SNTA, (that has unrecognized value), the rush to get in can be pretty amazing. The past week was probably just the beginning of a tremendous run for SNTA. This next week may result in a high percentage of short shares passing over to long positions as a strategy to hedge against losses. The nemesis that looms over the shorts like a dark cloud is the recent run coupled with big volume This next week is going to be great for SNTA shareholders. GLTA